Renalytix AI PLC Result of AGM (2137O)
September 30 2019 - 10:37AM
UK Regulatory
TIDMRENX
RNS Number : 2137O
Renalytix AI PLC
30 September 2019
Renalytix AI plc
("RenalytixAI" or the "Company")
Result of AGM
Renalytix AI plc (AIM: RENX), a developer of artificial
intelligence-enabled clinical diagnostics for kidney disease,
announces at its annual general meeting held earlier today, the
following resolutions were passed on a show of hands with the table
below summarising proxy votes:
Resolution Votes for* Votes against Votes withheld
To receive the audited accounts
1. of the Company 24,481,789 22 0
----------------------------------------- ----------- -------------- ---------------
2. To re-elect Julian Baines 24,481,789 22 0
----------------------------------------- ----------- -------------- ---------------
3. To re-elect Christopher Mills 20,570,985 3,910,826 0
----------------------------------------- ----------- -------------- ---------------
4. To re-elect Richard Evans 24,481,789 22 0
----------------------------------------- ----------- -------------- ---------------
5. To re-elect Fergus Fleming 24,481,789 22 0
----------------------------------------- ----------- -------------- ---------------
6. To elect Doctor Erik Lium 24,481,789 22 0
----------------------------------------- ----------- -------------- ---------------
7. To elect James McCullough 24,481,789 22 0
----------------------------------------- ----------- -------------- ---------------
8. To elect Barbara Murphy 24,481,811 0 0
----------------------------------------- ----------- -------------- ---------------
To re-appoint the auditors PKF
Littlejohn LLP and authorise
9. the Directors to fix their remuneration 24,481,789 22 0
----------------------------------------- ----------- -------------- ---------------
To authorise the directors to
replace the existing authority
to allot shares in the Company
in connection with s551 of the
10. Companies Act 2006 24,481,789 22 0
----------------------------------------- ----------- -------------- ---------------
To authorise the directors to
allot Relevant Securities as
if s561 of the Companies Act
11. 2006 did not apply 23,769,147 702,664 10,000
----------------------------------------- ----------- -------------- ---------------
*Any proxy appointments, which gave discretion to the Chairman
have been included in the 'For' votes total.
For further information, please contact:
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser & Joint Broker) Tel: 020 7710 7600
Alex Price / Jonathan Senior / Ben Maddison
N+1 Singer (Joint Broker) Tel: 020 7496 3000
Aubrey Powell / James White / George Tzimas (Corporate Finance)
Tom Salvesen / Mia Gardner (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391
303
About Kidney Disease
Kidney disease is now recognized as a public health epidemic
affecting over 850 million people globally. In the United States
alone, over 40 million people are classified as having chronic
kidney disease, with nearly 50 percent of individuals with advanced
(Stage IV) disease unaware of the severity of their reduced kidney
function. As a result, many patients progress to kidney failure in
an unplanned manner, ending up having dialysis in the emergency
room without ever seeing a clinical specialist, such as a
nephrologist. Every day 13 patients die in the United States while
waiting for a kidney transplant.
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled
clinical diagnostic solutions for kidney disease, one of the most
common and costly chronic medical conditions globally. The
Company's solutions are being designed to make significant
improvements in kidney disease diagnosis and prognosis, clinical
care, patient stratification for drug clinical trials, and drug
target discovery. For more information, visit renalytixai.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGEASNEDDANEFF
(END) Dow Jones Newswires
September 30, 2019 11:37 ET (15:37 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024